Charles River Laboratories International, Inc. (NYSE:CRL) Given Consensus Rating of “Moderate Buy” by Brokerages

Charles River Laboratories International, Inc. (NYSE:CRL) has earned an average recommendation of “Moderate Buy” from the fifteen ratings firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, four have given a hold rating and ten have given a buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $207.6923.

A number of research firms recently commented on CRL. UBS Group increased their target price on shares of Charles River Laboratories International from $170.00 to $175.00 and gave the company a “neutral” rating in a research report on Wednesday, February 25th. TD Cowen dropped their target price on shares of Charles River Laboratories International from $251.00 to $235.00 and set a “buy” rating on the stock in a research report on Friday, February 20th. Evercore reaffirmed an “outperform” rating and issued a $220.00 target price on shares of Charles River Laboratories International in a research report on Friday, May 8th. Mizuho set a $192.00 target price on shares of Charles River Laboratories International in a research report on Friday, May 8th. Finally, Royal Bank Of Canada began coverage on shares of Charles River Laboratories International in a research report on Tuesday, April 14th. They issued an “outperform” rating and a $215.00 target price on the stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of CRL. Jones Financial Companies Lllp grew its position in Charles River Laboratories International by 167.6% during the 1st quarter. Jones Financial Companies Lllp now owns 1,715 shares of the medical research company’s stock worth $253,000 after purchasing an additional 1,074 shares during the last quarter. Empowered Funds LLC purchased a new position in Charles River Laboratories International during the 1st quarter worth $418,000. American Century Companies Inc. grew its position in Charles River Laboratories International by 41.9% during the 2nd quarter. American Century Companies Inc. now owns 5,469 shares of the medical research company’s stock worth $830,000 after purchasing an additional 1,616 shares during the last quarter. Brown Advisory Inc. grew its position in Charles River Laboratories International by 5.1% during the 2nd quarter. Brown Advisory Inc. now owns 2,333 shares of the medical research company’s stock worth $354,000 after purchasing an additional 114 shares during the last quarter. Finally, California Public Employees Retirement System grew its position in Charles River Laboratories International by 3.9% during the 2nd quarter. California Public Employees Retirement System now owns 84,605 shares of the medical research company’s stock worth $12,837,000 after purchasing an additional 3,198 shares during the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Charles River Laboratories International Trading Up 5.0%

NYSE CRL opened at $164.56 on Thursday. The company has a debt-to-equity ratio of 0.90, a current ratio of 1.36 and a quick ratio of 1.03. The firm’s fifty day moving average price is $168.04 and its 200 day moving average price is $181.10. The company has a market capitalization of $7.93 billion, a price-to-earnings ratio of -43.77, a price-to-earnings-growth ratio of 1.79 and a beta of 1.44. Charles River Laboratories International has a 12 month low of $132.58 and a 12 month high of $228.88.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Thursday, May 7th. The medical research company reported $2.06 EPS for the quarter, beating analysts’ consensus estimates of $1.96 by $0.10. The firm had revenue of $995.83 million for the quarter, compared to the consensus estimate of $977.46 million. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The company’s revenue was up 1.2% on a year-over-year basis. During the same period last year, the firm posted $2.34 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. On average, sell-side analysts expect that Charles River Laboratories International will post 11.05 earnings per share for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.